Remdesivir for Treatment of COVID-19 Requiring Oxygen Support: A Cross-Study Comparison From 2 Large, Open-Label Studies

Dahlene N. Fusco, Ivana Malenica, Huldrych F. Günthard, Samir K. Gupta, Dax Kurbegov, Bindu Balani, Susan Olender, Judith A. Aberg, Laura Telep, Yuan Tian, Christiana Blair, George Y. Wu, Richard Haubrich, Chen‐Yu Wang, Anand P. Chokkalingam, Anu Osinusi, Clemens‐Martin Wendtner, Robert GottliebClinical 2024 · DOI

Abstract

Remdesivir plus early-2020 SOC was associated with a 54% lower mortality risk and shorter hospital stays compared with SOC alone in patients hospitalized with COVID-19 requiring oxygen support. Clinical Trials Registration. ClinicalTrials.gov NCT04292899 and EUPAS34303.
BibTeX
@inproceedings{fusco2024remdesivir,
  author = {Dahlene N. Fusco and Ivana Malenica and Huldrych F. Günthard and Samir K. Gupta and Dax Kurbegov and Bindu Balani and Susan Olender and Judith A. Aberg and Laura Telep and Yuan Tian and Christiana Blair and George Y. Wu and Richard Haubrich and Chen‐Yu Wang and Anand P. Chokkalingam and Anu Osinusi and Clemens‐Martin Wendtner and Robert Gottlieb},
  title = {{Remdesivir for Treatment of COVID-19 Requiring Oxygen Support: A Cross-Study Comparison From 2 Large, Open-Label Studies}},
  booktitle = {Clinical},
  year = {2024},
  doi = {10.1093/cid/ciae336},
}

Loading related content...

Figure